Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47) 47
science & technology (37) 37
life sciences & biomedicine (36) 36
female (33) 33
male (33) 33
middle aged (33) 33
oncology (32) 32
aged (30) 30
beer (29) 29
biochemistry (29) 29
chemistry (29) 29
compositions or test papers therefor (29) 29
condition-responsive control in microbiological orenzymological processes (29) 29
enzymology (29) 29
measuring or testing processes involving enzymes, nucleicacids or microorganisms (29) 29
metallurgy (29) 29
microbiology (29) 29
mutation or genetic engineering (29) 29
organic chemistry (29) 29
processes of preparing such compositions (29) 29
spirits (29) 29
vinegar (29) 29
wine (29) 29
adult (26) 26
biological and medical sciences (22) 22
medical sciences (22) 22
tumors (21) 21
aged, 80 and over (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
colorectal neoplasms - drug therapy (19) 19
treatment outcome (16) 16
chemotherapy (15) 15
colorectal neoplasms - genetics (15) 15
compositions thereof (15) 15
culture media (15) 15
derivatives thereof (15) 15
heterocyclic compounds (15) 15
human necessities (15) 15
hygiene (15) 15
medical or veterinary science (15) 15
microorganisms or enzymes (15) 15
nucleic acids (15) 15
nucleosides (15) 15
nucleotides (15) 15
preparations for medical, dental, or toilet purposes (15) 15
propagating, preserving or maintaining microorganisms (15) 15
specific therapeutic activity of chemical compounds ormedicinal preparations (15) 15
sugars (15) 15
colorectal cancer (13) 13
fluorouracil - administration & dosage (13) 13
antineoplastic agents (11) 11
cancer (11) 11
gastroenterology. liver. pancreas. abdomen (11) 11
polymorphism, genetic (11) 11
hematology, oncology and palliative medicine (10) 10
organoplatinum compounds - administration & dosage (10) 10
pharmacology. drug treatments (10) 10
stomach. duodenum. small intestine. colon. rectum. anus (10) 10
survival rate (10) 10
antineoplastic agents - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
polymorphism, restriction fragment length (9) 9
retrospective studies (9) 9
cisplatin - administration & dosage (8) 8
colorectal neoplasms - pathology (8) 8
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (8) 8
fluorouracil - therapeutic use (8) 8
genotype (8) 8
peptides (8) 8
prognosis (8) 8
survival analysis (8) 8
thymidylate synthase - genetics (8) 8
gene expression regulation, neoplastic (7) 7
kaplan-meier estimate (7) 7
leucovorin - administration & dosage (7) 7
oxaliplatin (7) 7
pharmacogenetics (7) 7
polymorphism (7) 7
adenocarcinoma - drug therapy (6) 6
cancer therapies (6) 6
care and treatment (6) 6
colorectal neoplasms - enzymology (6) 6
colorectal neoplasms - mortality (6) 6
disease progression (6) 6
disease-free survival (6) 6
dna repair (6) 6
follow-up studies (6) 6
metastasis (6) 6
polymerase chain reaction (6) 6
risk factors (6) 6
stomach neoplasms - drug therapy (6) 6
time factors (6) 6
animals (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
biomarkers, tumor - genetics (5) 5
chemotherapy, adjuvant (5) 5
dna primers (5) 5
lung neoplasms - drug therapy (5) 5
medical research (5) 5
mutation (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
by Folprecht, Gunnar, Dr and Gruenberger, Thomas, Prof and Bechstein, Wolf O, Prof and Raab, Hans-Rudolf, Prof and Lordick, Florian, MD and Hartmann, Jörg T, Prof and Lang, Hauke, Prof and Frilling, Andrea, Prof and Stoehlmacher, Jan, MD and Weitz, Jürgen, MD and Konopke, Ralf, MD and Stroszczynski, Christian, Prof and Liersch, Torsten, MD and Ockert, Detlev, Prof and Herrmann, Thomas, Prof and Goekkurt, Eray, MD and Parisi, Fabio, PhD and Köhne, Claus-Henning, Prof
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text TFAP2E–DKK4 and Chemoresistance in Colorectal Cancer
by Ebert, Matthias P.A and Tänzer, Marc and Balluff, Benjamin and Burgermeister, Elke and Kretzschmar, Antje Karen and Hughes, David J and Tetzner, Reimo and Lofton-Day, Catherine and Rosenberg, Robert and Reinacher-Schick, Anke C and Schulmann, Karsten and Tannapfel, Andrea and Hofheinz, Ralf and Röcken, Christoph and Keller, Gisela and Langer, Rupert and Specht, Katja and Porschen, Rainer and Stöhlmacher-Williams, Jan and Schuster, Tibor and Ströbel, Philipp and Schmid, Roland M
The New England journal of medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 44 - 53
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Gene Expression | Microsatellite Instability | Colorectal Neoplasms - genetics | Epigenesis, Genetic | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Intercellular Signaling Peptides and Proteins - genetics | Male | Antineoplastic Agents - therapeutic use | Chemoradiotherapy | Transcription Factor AP-2 - metabolism | Colorectal Neoplasms - therapy | DNA Methylation | Drug Resistance, Neoplasm - genetics | Transcription Factor AP-2 - genetics | DNA - analysis | Colorectal Neoplasms - drug therapy | Cell Line, Tumor | Female | Aged | Mutation | Chemotherapy | Usage | Patient outcomes | Colorectal cancer | Research | Drug therapy | Drug resistance | Cancer | Transcription factors | Peptides | Pathogenesis | Cloning | Colorectal carcinoma | Chemoresistance | Biology | Metastasis | Microsatellite instability | Tumor cell lines | Gene expression | Patients | Metastases | Irinotecan | Oxaliplatin | Plasmids | DNA methylation | Genetic testing | Methylation | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
by Hegewisch-Becker, Susanna, Prof and Graeven, Ullrich, MD and Lerchenmüller, Christian A, MD and Killing, Birgitta, MD and Depenbusch, Reinhard, MD and Steffens, Claus-Christoph, MD and Al-Batran, Salah-Eddin, Prof and Lange, Thoralf, Prof and Dietrich, Georg, MD and Stoehlmacher, Jan, Prof and Tannapfel, Andrea, Prof and Reinacher-Schick, Anke, Prof and Quidde, Julia, MD and Trarbach, Tanja, MD and Hinke, Axel, PhD and Schmoll, Hans-Joachim, Prof and Arnold, Dirk, Prof
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Leucovorin - therapeutic use | Maintenance Chemotherapy | Angiogenesis Inhibitors - adverse effects | Colorectal Neoplasms - mortality | Risk Factors | Kaplan-Meier Estimate | Capecitabine - therapeutic use | Disease Progression | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Colorectal Neoplasms - pathology | Drug Substitution | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Colorectal cancer | Product development | Metastasis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
by Hoffknecht, Petra and Tufman, Amanda and Wehler, Thomas and Pelzer, Theo and Wiewrodt, Rainer and Schütz, Martin and Serke, Monika and Stöhlmacher-Williams, Jan and Märten, Angela and Maria Huber, Rudolf and Dickgreber, Nicolas J and for the Afatinib Compassionate Use Consortium (ACUC) and ACUC and Afatinib Compassionate Use Consortium (ACUC)
Journal of thoracic oncology, ISSN 1556-0864, 01/2015, Volume 10, Issue 1, pp. 156 - 163
ErbB family blocker | Non–small-cell lung cancer | Compassionate use program | Afatinib | Central nervous system metastasis | Non-small-cell lung cancer | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - enzymology | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Treatment Outcome | Brain Neoplasms - drug therapy | Disease Progression | Brain Neoplasms - secondary | Meningeal Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Meningeal Neoplasms - secondary
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
by Al-Batran, Salah-Eddin and Homann, Nils and Pauligk, Claudia and Goetze, Thorsten O and Meiler, Johannes and Kasper, Stefan and Kopp, Hans-Georg and Mayer, Frank and Haag, Georg Martin and Luley, Kim and Lindig, Udo and Schmiegel, Wolff and Pohl, Michael and Stoehlmacher, Jan and Folprecht, Gunnar and Probst, Stephan and Prasnikar, Nicole and Fischbach, Wolfgang and Mahlberg, Rolf and Trojan, Jörg and Koenigsmann, Michael and Martens, Uwe M and Thuss-Patience, Peter and Egger, Matthias and Block, Andreas and Heinemann, Volker and Illerhaus, Gerald and Moehler, Markus and Schenk, Michael and Kullmann, Frank and Behringer, Dirk M and Heike, Michael and Pink, Daniel and Teschendorf, Christian and Löhr, Carmen and Bernhard, Helga and Schuch, Gunter and Rethwisch, Volker and von Weikersthal, Ludwig Fischer and Hartmann, Jörg T and Kneba, Michael and Daum, Severin and Schulmann, Karsten and Weniger, Jörg and Belle, Sebastian and Gaiser, Timo and Oduncu, Fuat S and Güntner, Martina and Hozaeel, Wael and Reichart, Alexander and Jäger, Elke and Kraus, Thomas and Mönig, Stefan and Bechstein, Wolf O and Schuler, Martin and Schmalenberg, Harald and Hofheinz, Ralf D and FLOT4-AIO Investigators
The Lancet (British edition), ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Evidence-based medicine | Metastases | Confidence intervals | Infusion | Oxaliplatin | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
by Yoshinori Shirota and Jan Stoehlmacher and Jan Brabender and Yi-Ping Xiong and Hiroyuki Uetake and Kathleen D. Danenberg and Susan Groshen and Denise D. Tsao-Wei and Peter V. Danenberg and Heinz-Josef Lenz
Journal of clinical oncology, ISSN 0732-183X, 12/2001, Volume 19, Issue 23, pp. 4298 - 4304
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | RNA, Messenger - metabolism | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | DNA-Binding Proteins | Colorectal Neoplasms - mortality | Thymidylate Synthase - metabolism | California | DNA Primers | Reverse Transcriptase Polymerase Chain Reaction | Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endonucleases | Survival Analysis | Aged | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
by Salah-Eddin Al-Batran and Joerg Thomas Hartmann and Stephan Probst and Harald Schmalenberg and Stephan Hollerbach and Ralf Hofheinz and Volker Rethwisch and Gernot Seipelt and Nils Homann and Gerhard Wilhelm and Gunter Schuch and Jan Stoehlmacher and Hans Günter Derigs and Susanna Hegewisch-Becker and Johannes Grossmann and Claudia Pauligk and Akin Atmaca and Carsten Bokemeyer and Alexander Knuth and Elke Jäger and Arbeitsgemeinschaft Internistische Onkologie
Journal of clinical oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1435 - 1442
Biological and medical sciences | Medical sciences | Tumors | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
by Sebastian, Martin and Schröder, Andreas and Scheel, Birgit and Hong, Henoch S and Muth, Anke and von Boehmer, Lotta and Zippelius, Alfred and Mayer, Frank and Reck, Martin and Atanackovic, Djordje and Thomas, Michael and Schneller, Folker and Stöhlmacher, Jan and Bernhard, Helga and Gröschel, Andreas and Lander, Thomas and Probst, Jochen and Strack, Tanja and Wiegand, Volker and Gnad-Vogt, Ulrike and Kallen, Karl-Josef and Hoerr, Ingmar and von der Muelbe, Florian and Fotin-Mleczek, Mariola and Knuth, Alexander and Koch, Sven D
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 5/2019, Volume 68, Issue 5, pp. 799 - 812
Immunology | Medicine & Public Health | Active cancer immunotherapy | CV9201 | Non-small cell lung cancer | Oncology | Cancer Research | Clinical trial | mRNA | Immunomonitoring | Life Sciences & Biomedicine | Science & Technology | Squamous cell carcinoma | Care and treatment | Oncology, Experimental | Clinical trials | Development and progression | Lung cancer, Small cell | Research | B cells | Lung cancer, Non-small cell | T cells | Messenger RNA | Immunotherapy | Drug therapy | Cancer | Antigens | Lung cancer | Melanoma | Non-small cell lung carcinoma | Lymphocytes T | Survivin | Immunoglobulin D | Patients | Esophagus | Metastases | Lymphocytes B | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
by Folprecht, Gunnar and Hamann, Susanne and Schütte, Katharina and Trarbach, Tanja and Stoehlmacher-Williams, Jan and Ehninger, Gerhard
BMC cancer, ISSN 1471-2407, 07/2014, Volume 14, Issue 1, pp. 521 - 521
Irinotecan | Chemotherapy | Oxaliplatin | Phase I | Cetuximab | Metastatic colorectal cancer | 5-FU | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Maximum Tolerated Dose | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Liver Neoplasms - secondary | Organoplatinum Compounds - adverse effects | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
by Eray Goekkurt and Salah-Eddin Al-Batran and Jörg T. Hartmann and Ulrike Mogck and Gunter Schuch and Michael Kramer and Elke Jaeger and Carsten Bokemeyer and Gerhard Ehninger and Jan Stoehlmacher
Journal of clinical oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 17, pp. 2863 - 2873
Biological and medical sciences | Medical sciences | Tumors | Stomach Neoplasms - genetics | Pharmacogenetics - methods | Humans | Middle Aged | Male | Clinical Trials as Topic | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Adenocarcinoma - genetics | Aged | Organoplatinum Compounds - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights